vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and RLI CORP (RLI). Click either name above to swap in a different company.
RLI CORP is the larger business by last-quarter revenue ($465.7M vs $281.3M, roughly 1.7× Guardant Health, Inc.). RLI CORP runs the higher net margin — 19.6% vs -45.7%, a 65.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 6.1%). RLI CORP produced more free cash flow last quarter ($155.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
RLI Corp. is an American insurance company specializing in property insurance and casualty insurance. It is headquartered in Peoria, Illinois.
GH vs RLI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $465.7M |
| Net Profit | $-128.5M | $91.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 24.4% |
| Net Margin | -45.7% | 19.6% |
| Revenue YoY | 39.4% | 6.1% |
| Net Profit YoY | -15.8% | 123.1% |
| EPS (diluted) | $-1.01 | $1.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $465.7M | ||
| Q3 25 | $265.2M | $509.3M | ||
| Q2 25 | $232.1M | $499.8M | ||
| Q1 25 | $203.5M | $407.7M | ||
| Q4 24 | $201.8M | $439.1M | ||
| Q3 24 | $191.5M | $470.0M | ||
| Q2 24 | $177.2M | $416.4M | ||
| Q1 24 | $168.5M | $444.8M |
| Q4 25 | $-128.5M | $91.2M | ||
| Q3 25 | $-92.7M | $124.6M | ||
| Q2 25 | $-99.9M | $124.3M | ||
| Q1 25 | $-95.2M | $63.2M | ||
| Q4 24 | $-111.0M | $40.9M | ||
| Q3 24 | $-107.8M | $95.0M | ||
| Q2 24 | $-102.6M | $82.0M | ||
| Q1 24 | $-115.0M | $127.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 24.4% | ||
| Q3 25 | -37.3% | 30.9% | ||
| Q2 25 | -45.9% | 31.3% | ||
| Q1 25 | -54.6% | 19.3% | ||
| Q4 24 | -62.4% | 10.8% | ||
| Q3 24 | -61.3% | 24.9% | ||
| Q2 24 | -56.8% | 24.8% | ||
| Q1 24 | -59.2% | 36.0% |
| Q4 25 | -45.7% | 19.6% | ||
| Q3 25 | -35.0% | 24.5% | ||
| Q2 25 | -43.0% | 24.9% | ||
| Q1 25 | -46.8% | 15.5% | ||
| Q4 24 | -55.0% | 9.3% | ||
| Q3 24 | -56.3% | 20.2% | ||
| Q2 24 | -57.9% | 19.7% | ||
| Q1 24 | -68.2% | 28.8% |
| Q4 25 | $-1.01 | $1.00 | ||
| Q3 25 | $-0.74 | $1.35 | ||
| Q2 25 | $-0.80 | $1.34 | ||
| Q1 25 | $-0.77 | $0.68 | ||
| Q4 24 | $-0.90 | $-2.87 | ||
| Q3 24 | $-0.88 | $2.06 | ||
| Q2 24 | $-0.84 | $1.78 | ||
| Q1 24 | $-0.94 | $2.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.8B |
| Total Assets | $2.0B | $6.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | $100.0M | ||
| Q2 25 | $1.1B | $100.0M | ||
| Q1 25 | $1.1B | $100.0M | ||
| Q4 24 | $1.1B | $100.0M | ||
| Q3 24 | — | $100.0M | ||
| Q2 24 | — | $100.0M | ||
| Q1 24 | — | $100.0M |
| Q4 25 | $-99.3M | $1.8B | ||
| Q3 25 | $-354.5M | $1.9B | ||
| Q2 25 | $-305.5M | $1.7B | ||
| Q1 25 | $-250.8M | $1.6B | ||
| Q4 24 | $-139.6M | $1.5B | ||
| Q3 24 | $-60.1M | $1.7B | ||
| Q2 24 | $-1.6M | $1.6B | ||
| Q1 24 | $68.3M | $1.5B |
| Q4 25 | $2.0B | $6.2B | ||
| Q3 25 | $1.3B | $6.2B | ||
| Q2 25 | $1.3B | $6.0B | ||
| Q1 25 | $1.3B | $5.7B | ||
| Q4 24 | $1.5B | $5.6B | ||
| Q3 24 | $1.5B | $5.8B | ||
| Q2 24 | $1.6B | $5.5B | ||
| Q1 24 | $1.7B | $5.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.06× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $156.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $155.0M |
| FCF MarginFCF / Revenue | -19.3% | 33.3% |
| Capex IntensityCapex / Revenue | 9.9% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $608.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $156.8M | ||
| Q3 25 | $-35.4M | $179.2M | ||
| Q2 25 | $-60.3M | $174.7M | ||
| Q1 25 | $-62.7M | $103.5M | ||
| Q4 24 | $-64.5M | $128.1M | ||
| Q3 24 | $-51.1M | $219.4M | ||
| Q2 24 | $-94.0M | $141.8M | ||
| Q1 24 | $-30.3M | $70.9M |
| Q4 25 | $-54.2M | $155.0M | ||
| Q3 25 | $-45.8M | $177.8M | ||
| Q2 25 | $-65.9M | $173.4M | ||
| Q1 25 | $-67.1M | $102.5M | ||
| Q4 24 | $-83.4M | $127.6M | ||
| Q3 24 | $-55.3M | $219.0M | ||
| Q2 24 | $-99.1M | $139.1M | ||
| Q1 24 | $-37.2M | $69.9M |
| Q4 25 | -19.3% | 33.3% | ||
| Q3 25 | -17.3% | 34.9% | ||
| Q2 25 | -28.4% | 34.7% | ||
| Q1 25 | -33.0% | 25.1% | ||
| Q4 24 | -41.3% | 29.0% | ||
| Q3 24 | -28.9% | 46.6% | ||
| Q2 24 | -55.9% | 33.4% | ||
| Q1 24 | -22.1% | 15.7% |
| Q4 25 | 9.9% | 0.4% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 2.4% | 0.3% | ||
| Q1 25 | 2.2% | 0.3% | ||
| Q4 24 | 9.4% | 0.1% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 2.9% | 0.7% | ||
| Q1 24 | 4.1% | 0.2% |
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.64× | ||
| Q4 24 | — | 3.13× | ||
| Q3 24 | — | 2.31× | ||
| Q2 24 | — | 1.73× | ||
| Q1 24 | — | 0.55× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RLI
| Casualty Segment | $246.8M | 53% |
| Property Insurance Segment | $122.5M | 26% |
| Other | $59.3M | 13% |
| Surety Insurance Segment | $37.1M | 8% |
